Application of Immuno-PET in Antibody–Drug Conjugate Development
Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective therapies as well as more accurately determini...
Saved in:
Main Authors: | Kendra S. Carmon PhD, Ali Azhdarinia PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-10-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012118801223 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adamantane/Cucurbituril: A Potential Pretargeted Imaging Strategy in Immuno-PET
by: Martin G. Strebl PhD, et al.
Published: (2018-10-01) -
Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
by: Elaine M. Jagoda PhD, et al.
Published: (2019-04-01) -
Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications
by: Hamideh Zarrinmayeh PhD, et al.
Published: (2020-06-01) -
Preclinical PET Neuroimaging of [C]Bexarotene
by: Benjamin H. Rotstein PhD, et al.
Published: (2016-08-01) -
Detecting Demyelination by PET: The Lesion as Imaging Target
by: Pedro Brugarolas PhD, et al.
Published: (2018-07-01)